Literature DB >> 11304651

Nicardipine to control mean arterial pressure after cardiothoracic surgery in infants and children.

J D Tobias1.   

Abstract

Nicardipine is the first intravenously administered dihydropyridine calcium channel blocker. Its primary physiologic action includes vasodilatation with limited effects on the inotropic and dromotropic function of the myocardium. Several previous reports document its use in adult patients for pharmacologic control of blood pressure. The current report describes the use of nicardipine to control mean arterial pressure (MAP) in nine infants and children after cardiothoracic surgical procedures. The patients ranged in age from 6 days to 9 years (mean, 3.3 +/- 4.1 years) and in weight from 4.1 to 49 kg (mean, 15.3 +/- 14.4). The surgical procedures included aortic coarctation repair (three), repair of tetralogy of Fallot (two), arterial switch for transposition of the great vessels (two), pulmonary valvotomy (one), and aortic valvotomy (one). The target systolic blood pressure was 90 mm Hg in patients younger than 4 years of age and < or = 110 mm Hg in patients 5 years of age or older. The nicardipine infusion was started at 5 microg/kg/min in all patients. The target blood pressure was achieved within 15 minutes in eight of nine patients. One patient required an initial infusion rate of 10 microg/kg/min to achieve the target blood pressure. The maintenance infusion rate varied from 2.5 to 5.5 mcg/k/min (mean 3.0 +/- 1.1). The duration of the infusion varied from 30 to 42 hours (mean, 37.4 +/- 4.2). In the nine patients, nicardipine was infused for a total of 337 hours. No adverse effects such as excessive hypotension were noted. Nicardipine is an effective agent for controlling MAP after cardiothoracic surgical procedures in infants and children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304651     DOI: 10.1097/00045391-200101000-00002

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  10 in total

Review 1.  Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications.

Authors:  Monique P Curran; Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 2.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

3.  Coarctation of the aorta associated with Dandy-Walker variant.

Authors:  Li Zhou; George K Lui; Rajesh Shenoy; Cynthia C Taub
Journal:  J Cardiovasc Dis Res       Date:  2013-08-20

Review 4.  Evaluation and management of elevated blood pressures in hospitalized children.

Authors:  Abanti Chaudhuri; Scott M Sutherland
Journal:  Pediatr Nephrol       Date:  2018-08-31       Impact factor: 3.714

Review 5.  A review of calcium channel antagonists in the treatment of pediatric hypertension.

Authors:  Shobha Sahney
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 6.  The management of hypertensive emergencies in children after stem cell transplantation.

Authors:  D G Horn; M N Trame; G Hempel
Journal:  Int J Clin Pharm       Date:  2011-03-12

Review 7.  Pharmacologic Control of Blood Pressure in Infants and Children.

Authors:  Joseph D Tobias; Aymen Naguib; Janet Simsic; Catherine D Krawczeski
Journal:  Pediatr Cardiol       Date:  2020-09-11       Impact factor: 1.655

Review 8.  Evaluation and treatment of hypertensive crises in children.

Authors:  Deborah R Stein; Michael A Ferguson
Journal:  Integr Blood Press Control       Date:  2016-03-16

9.  Clevidipine for perioperative blood pressure control in infants and children.

Authors:  Joseph D Tobias; David B Tulman; Sergio D Bergese
Journal:  Pharmaceuticals (Basel)       Date:  2013-01-15

10.  Clevidipine resistance in a patient taking aripiprazole and methylphenidate.

Authors:  M Alysse Jacklen; Jason A Campagna; Joseph D Tobias
Journal:  J Exp Pharmacol       Date:  2014-10-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.